Systems biology, complexity, and the impact on antiepileptic drug discovery

Epilepsy and Behavior

Volumn 38, Issue , 2014, Pages 131-142

  Margineanu, Doru Georg ^a  

^a UNIVERSITY OF MONS   (Belgium)

Author keywords

Antiepileptic drug; Drug discovery; Drug resistance in epilepsy; Modeling; Multitarget drug; Phenotypic screening; Polypharmacology; Systems biology; Systems network pharmacology

Indexed keywords

ANTICONVULSIVE AGENT;

DRUG DEVELOPMENT; ENCEPHALITIS; EPILEPSY; GLIA; HUMAN; NERVE CELL EXCITABILITY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOLOGY; REVIEW; SYSTEMS BIOLOGY; DRUG RESISTANCE; PROCEDURES;

ANTICONVULSANTS; DRUG DISCOVERY; DRUG RESISTANCE; EPILEPSY; HUMANS; SYSTEMS BIOLOGY;

EID: 84910646137     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.08.029     Document Type: Review

References (167)

1. Reynolds E.H. Milestones in epilepsy. Epilepsia 2009, 50:338-342.
2. Reynolds E.H., Rodin E. The clinical concept of epilepsy. Epilepsia 2009, 50(Suppl. 3):2-7.
3. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013, 103:2-30.
4. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
5. Wahab A., Albus K., Gabriel S., Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia 2010, 51(Suppl. 3):154-159.
6. Brodie M.J., Covanis A., Gil-Nagel A., Lerche H., Perucca E., Sills G.J., et al. Antiepileptic drug therapy: does mechanism of action matter?. Epilepsy Behav 2011, 21(4):331-341.
7. Löscher W., Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010, 62:668-700.
8. Temkin N.R., Jarell A.D., Anderson G.D. Antiepileptogenic agents. How close are we?. Drugs 2001, 61:1045-1055.
9. Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Curr 2011, 11:9-11.
10. Galanopoulou A.S., Buckmaster P.S., Staley K.J., Moshe S.L., Perucca E., Engel J., et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012, 53(3):571-582.
11. Löscher W., Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011, 52:657-678.
12. Ideker T., Galitski T., Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001, 2:343-372.
13. Kitano H. Systems biology: a brief overview. Science 2002, 295:1662-1664.
14. Barabási A.L., Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004, 5:101-113.
15. Sauer U., Heinemann M., Zamboni N. Getting closer to the whole picture. Science 2007, 316:550-551.
16. Garcia-Cairasco N. Puzzling challenges in contemporary neuroscience: insights from complexity and emergence in epileptogenic circuits. Epilepsy Behav 2009, 14(Suppl. 1):54-63.
17. Avanzini G., Manganotti P., Meletti S., Moshé S.L., Panzica F., Wolf P., et al. The system epilepsies: a pathophysiological hypothesis. Epilepsia 2012, 53:771-778.
18. Margineanu D.G. Systems biology impact on antiepileptic drug discovery. Epilepsy Res 2012, 98:104-115.
19. Tejada J., Costa K.M., Bertti P., Garcia-Cairasco N. The epilepsies: complex challenges needing complex solutions. Epilepsy Behav 2013, 26:212-228.
20. Keith C.T., Borisy A.A., Stockwel B.R. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005, 4:71-78.
21. Hopkins A.L. Network pharmacology. Network biology illuminates our understanding of drug action. Nat Biotechnol 2007, 24:1110-1111.
22. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4:682-690.
23. Booth B., Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004, 3:451-456.
24. Bunnage M.E. Getting pharmaceutical R&D back on target. Nat Chem Biol 2011, 7:335-339.
25. Pammolli F., Magazzini L., Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011, 10:428-438.
26. Scannell J.W., Blanckley A., Boldon H., Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012, 11:191-200.
27. Hood L., Perlmutter R.M. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 2004, 22:1215-1217.
28. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov Today 2005, 10:139-147.
29. Pujol A., Mosca R., Farrés J., Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010, 31:115-122.
30. Berger S.I., Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009, 25:2466-2472.
31. Boran A.D.W., Iyengar R. Systems pharmacology. Mt Sinai J Med 2010, 77:333-344.
32. Butcher E.C. Can cell systems biology rescue drug discovery?. Nat Rev Drug Discov 2005, 4:461-467.
33. von Bertalanffy L. General system theory: foundations, developments, applications 1968, Braziller, New York.
34. Lauffenburger D.A. Cell signaling pathways as control modules: complexity for simplicity?. Proc Natl Acad Sci U S A 2000, 97:5031-5033.
35. Westerhoff H.V., Palsson B.O. The evolution of molecular biology into systems biology. Nat Biotechnol 2004, 22:1249-1252.
36. Burrage K., Hood L., Ragan M.A. Advanced computing for systems biology. Brief Bioinform 2006, 7:390-398.
37. Schadt E.E., Sachs A., Friend S. Embracing complexity, inching closer to reality. Sci STKE 2005, 295:pe40.
38. Schadt E.E., Friend S.H., Shaywitz D.A. A network view of disease and compound screening. Nat Rev Drug Discov 2009, 8:286-295.
39. Hood L., Heath J.R., Phelps M.E., Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004, 306:640-643.
40. Villoslada P., Steinman L., Baranzini S.E. Systems biology and its application to the understanding of neurological diseases. Ann Neurol 2009, 65:124-139.
41. Noorbakhsh F., Overall C.M., Power C. Deciphering complex mechanisms in neuro-degenerative diseases: the advent of systems biology. Trends Neurosci 2009, 32:88-100.
42. Tononi G., Sporns O., Edelman G.M. A measure for brain complexity: relating functional segregation and integration in the nervous system. Proc Natl Acad Sci U S A 1994, 91:5033-5037.
43. Koch C., Laurent G. Complexity and the nervous system. Science 1999, 284:96-98.
44. Garcia-Cairasco N. Learning about brain physiology and complexity from the study of the epilepsies. Braz J Med Biol Res 2009, 42:76-86.
45. Margineanu D.G. Epileptic hypersynchrony revisited. Neuroreport 2010, 21:963-967.
46. McCormick D.A., Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001, 63:815-846.
47. Le Novère N., Hucka M., Mi H., Moodie S., Schreiber F., Sorokin A., et al. The systems biology graphical notation. Nat Biotechnol 2009, 27:735-741.
48. Lytton W.W. Computer modelling of epilepsy. Nat Rev Neurosci 2008, 9:626-637.
49. Stefanescu R.A., Shivakeshavan R.G., Talathi S.S. Computational models of epilepsy. Seizure 2012, 21:748-759.
50. Thomas E.A., Reid C.A., Berkovic S.F., Petrou S. Prediction by modeling that epilepsy may be caused by very small functional changes in ion channels. Arch Neurol 2009, 66:1225-1232.
51. Reid C.A., Berkovic S.F., Petrou S. Mechanisms of human inherited epilepsies. Prog Neurobiol 2009, 87:41-57.
52. Oliva M., Berkovic S.F., Petrou S. Sodium channels and the neurobiology of epilepsy. Epilepsia 2012, 53:1849-1859.
53. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Hauser W.A., Mathern G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
54. Margineanu D.G., Klitgaard H. Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery. Expert Opin Drug Discov 2009, 4:23-32.
55. Berg A.T. Identification of pharmacoresistant epilepsy. Neurol Clin 2009, 27:1003-1013.
56. Pati S., Alexopoulos A.V. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 2010, 77:457-467.
57. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N Engl J Med 2011, 365(10):919-926.
58. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:315-319.
59. Laroche S.M., Helmers S.L. The new antiepileptic drugs - scientific review. J Am Med Assoc 2004, 291:605-614.
60. Novartis Foundation Symposium No. 243. Mechanisms of Drug Resistance in Epilepsy: Lessons from Oncology 2002, Wiley, Chichester. G. Bock, J. Goode (Eds.).
61. Löscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005, 6:591-602.
62. Lazarowski A., Czornyj L., Lubienieki F., Girardi E., Vazquez S., D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007, 48(Suppl. 5):140-149.
63. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129:18-35.
64. Beck H. Plasticity of antiepileptic drug targets. Epilepsia 2007, 48(Suppl. 1):14-18.
65. Rambeck B., Jürgens U.H., May T.W., Pannek H.W., Behne F., Ebner A., et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006, 47:681-694.
66. Liu J.Y., Thom M., Catarino C.B., Martinian L., Figarella-Branger D., Bartolomei F., et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012, 135:3115-3133.
67. Baltes S., Fedrowitz M., Luna Tortos C., Potschka H., Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007, 320:331-343.
68. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52:333-346.
69. Löscher W., Sills G.J. Drug resistance in epilepsy: why is a simple explanation not enough?. Epilepsia 2007, 48:2370-2372.
70. Löscher W., Luna-Tortós C., Römermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 2011, 17:2808-2828.
71. Crowe A., Teoh Y.-K. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target 2006, 14:291-300.
72. Zhang C., Zuo Z., Kwan P., Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011, 52:1894-1904.
73. + channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003, 119:323-333.
74. 2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci 2002, 22:3645-3655.
75. Shah M.M., Anderson A.E., Leung V., Lin X., Johnston D. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. Neuron 2004, 44:495-508.
76. Poolos N.P., Migliore M., Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002, 5:767-774.
77. h in rat CA1 pyramidal cells. Epilepsia 2003, 44:150-156.
78. + channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003, 17:2648-2658.
79. --cotransporter, in epilepsy-associated malformations of cortical development. Neuroscience 2007, 145:185-196.
80. Munakata M., Watanabe M., Otsuki T., Nakama H., Arima K., Itoh M., et al. Altered distribution of KCC2 in cortical dysplasia in patients with intractable epilepsy. Epilepsia 2007, 48:837-844.
81. Sen A., Martinian L., Nikolic M., Walker M.C., Thom M., Sisodiya S.M. Increased NKCC1 expression in refractory human epilepsy. Epilepsy Res 2007, 74:220-227.
82. Aarli J.A., Fontana A. Immunological aspects of epilepsy. Epilepsia 1980, 21:451-457.
83. Aarli J.A. Immunological aspects of epilepsy. Brain Dev 1993, 15:41-49.
84. Aarli J.A. Epilepsy and the immune system. Arch Neurol 2000, 57:1689-1692.
85. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46:1724-1743.
86. Vezzani A., Rüegg S. Introduction. Epilepsia 2011, 52(Suppl. 3):1-4.
87. Vezzani A., French J., Bartfai T., Baram T.Z. The role of inflammation in epilepsy. Nat Rev Neurol 2011, 7:31-40.
88. Vezzani A., Auvin S., Ravizza T., Aronica E. Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. Jasper's basic mechanisms of the epilepsies [Internet] 2012, National Center for Biotechnology Information (US), Bethesda (MD), [http://www.ncbi.nlm.nih.gov/books/NBK98146/pdf/vezzani.pdf]. 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
89. Gorter J.A., van Vliet E.A., Aronica E., Breit T., Rauwerda H., Lopes da Silva F.H., et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 2006, 26:11083-11110.
90. Marchi N., Granata T., Freri E., Ciusani E., Ragona F., Puvenna V., et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One 2011, 6(3):e18200. 10.1371/journal.pone.0018200.
91. Volterra A., Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005, 6:626-640.
92. Steinhäuser C., Seifert G. Astrocyte dysfunction in epilepsy. Jasper's basic mechanisms of the epilepsies [Internet] 2012, National Center for Biotechnology Information (US), Bethesda (MD), [http://www.ncbi.nlm.nih.gov/books/NBK98180/pdf/steinhauser.pdf]. 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
93. Doherty M.J., Rostad S.W., Abson Kraemer D.L., Vossler D.G., Haltiner A.M. Neocortical gliosis in temporal lobe epilepsy: gender-based differences. Epilepsia 2007, 48:1455-1459.
94. Eid T., Williamson A., Lee T.S., Petroff O.A., de Lanerolle N.C. Glutamate and astrocytes - key players in human mesial temporal lobe epilepsy?. Epilepsia 2008, 49(Suppl. 2):42-52.
95. Oberheim N.A., Tian G.-F., Han X., Peng W., Takano T., Ransom B., et al. Loss of astrocytic domain organization in the epileptic brain. J Neurosci 2008, 28:3264-3276.
96. de Lanerolle N.C., Lee T.S. New facets of the neuropathology and molecular profile of human temporal lobe epilepsy. Epilepsy Behav 2005, 7:190-203.
97. Seifert G., Carmignoto G., Steinhäuser C. Astrocyte dysfunction in epilepsy. Brain Res Rev 2010, 63:212-221.
98. Binder D.K., Steinhäuser C. Functional changes in astroglial cells in epilepsy. Glia 2006, 54:358-368.
99. Seifert G., Schilling K., Steinhäuser C. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci 2006, 7:194-206.
100. Jabs R., Seifert G., Steinhäuser C. Astrocytic function and its alteration in the epileptic brain. Epilepsia 2008, 49(Suppl. 2):3-12.
101. Margineanu D.G., Klitgaard H. Can gap-junction blockade preferentially inhibit neuronal hypersynchrony vs. excitability?. Neuropharmacology 2001, 41:377-383.
102. Hinterkeuser S., Schröder W., Hager G., Seifert G., Blümcke I., Elger C.E., et al. Astrocytes in the hippocampus of patients with temporal lobe epilepsy display changes in potassium conductances. Eur J Neurosci 2000, 12:2087-2096.
103. Wallraff A., Kohling R., Heinemann U., Theis M., Willecke K., Steinhäuser C. The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci 2006, 26:5438-5447.
104. Amiry-Moghaddam M., Ottersen O.P. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003, 4:991-1001.
105. Nagelhus E.A., Mathiisen T.M., Ottersen O.P. Aquaporin-4 in the central nervous system: cellular and subcellular distribution and coexpression with Kir4.1. Neuroscience 2004, 129:905-913.
106. + homeostasis in the human epileptogenic hippocampus. Proc Natl Acad Sci U S A 2005, 102:1193-1198.
107. Rouach N., Avignone E., Même W., Koulakoff A., Venance L., Blomstrand F., et al. Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell 2002, 94:457-475.
108. Fonseca C.G., Green C.R., Nicholson L.F. Upregulation in astrocytic connexin 43 gap junction levels may exacerbate generalized seizures in mesial temporal lobe epilepsy. Brain Res 2002, 929:105-116.
109. Nilsen K.E., Kelso A.R.C., Cock H.R. Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. Epilepsia 2006, 47:1169-1175.
110. Voss L.J., Jacobson G., Sleigh J.W., Steyn-Ross A., Steyn-Ross M. Excitatory effects of gap junction blockers on cerebral cortex seizure-like activity in rats and mice. Epilepsia 2009, 50:1971-1978.
111. Voss L.J., Mutsaerts N., Sleigh J.W. Connexin36 gap junction blockade is ineffective at reducing seizure-like event activity in neocortical mouse slices. Epilepsy Res Treat 2010, [Article ID 310753]. 10.1155/2010/310753.
112. Beaumont M., Maccaferri G. Is connexin36 critical for GABAergic hypersynchronization in the hippocampus?. J Physiol 2011, 589:1663-1680.
113. Juszczak G.R., Swiergiel A.H. Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:181-198.
114. Connors B.W. Tales of a dirty drug: carbenoxolone, gap junctions, and seizures. Epilepsy Curr 2012, 12:66-68.
115. Volman V., Perc M., Bazhenov M. Gap junctions and epileptic seizures - two sides of the same coin?. PLoS One 2011, 6(5):e20572. 10.1371/journal.pone.0020572.
116. Ben Ari Y. Developing networks play a similar melody. Trends Neurosci 2001, 24:353-360.
117. Payne J.A., Rivera C., Voipio J., Kaila K. Cation-chloride co-transporters in neuronal communication, development and trauma. Trends Neurosci 2003, 26:199-206.
118. - transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory. Proc Natl Acad Sci U S A 2006, 103:8465-8468.
119. Avoli M., Louvel J., Pumain R., Köhling R. Cellular and molecular mechanisms of epilepsy in the human brain. Prog Neurobiol 2005, 77:166-200.
120. Majores M., Schoch S., Lie A., Becker A.J. Molecular neuropathology of temporal lobe epilepsy: complementary approaches in animal models and human disease tissue. Epilepsia 2007, 48(Suppl. 2):4-12.
121. Jones D. Pathways to cancer therapy. Nat Rev Drug Discov 2008, 7:875-876.
122. Stafstrom C.E. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 2010, 23:157-163.
123. Brodie M.J., Sills G.J. Combining AEDs - rational polytherapy?. Seizure 2011, 20:369-375.
124. Stephen L.J., Forsyth M., Kelly K., Brodie M.J. Antiepileptic drug combinations - have newer agents altered clinical outcomes?. Epilepsy Res 2012, 98:194-198.
125. Löscher W., Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002, 50:3-16.
126. Bianchi M.T., Pathmanathan J., Cash S.S. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med Hypotheses 2009, 72:297-305.
127. Schmidt D. Antiepileptic drug discovery: does mechanism of action matter?. Epilepsy Behav 2011, 21:342-343.
128. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
129. Simonato M., Löscher W., Cole A.J., Dudek F.E., Engel J., Kaminski R.M., et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012, 53:1860-1867.
130. Löscher W., Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Res 1994, 17:95-134.
131. Fredholm B., Abbott A. New targets for drug action: is high selectivity always beneficial?. Trends Pharmacol Sci 1990, 11:175-178.
132. Varela F., Lachaux J.P., Rodriguez E., Martinerie J. The brainweb: phase synchronization and large-scale integration. Nat Rev Neurosci 2001, 2:229-239.
133. Faingold C.L. Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action. Prog Neurobiol 2004, 72:55-85.
134. Loeb J.A. A human systems biology approach to discover new drug targets in epilepsy. Epilepsia 2010, 51(Suppl. 3):171-177.
135. Loeb J.A. Identifying targets for preventing epilepsy using systems biology. Neurosci Lett 2011, 497:205-212.
136. Rakhade S.N., Shah A.K., Agarwal R., Yao B., Asano E., Loeb J.A. Activity-dependent gene expression correlates with interictal spiking in human neocortical epilepsy. Epilepsia 2007, 48(Suppl. 5):86-95.
137. Barkmeier D.T., Loeb J.A. An animal model to study the clinical significance of interictal spiking. Clin EEG Neurosci 2009, 40:234-238.
138. Peterson R.T. Chemical biology and the limits of reductionism. Nat Chem Biol 2008, 4:635-638.
139. Stephen L.J., Brodie M.J. Seizure freedom with more than one antiepileptic drug. Seizure 2002, 11:349-351.
140. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 50(Suppl. 8):63-68.
141. Iskar M., Zeller G., Zhao X.-M., van Noort V., Bork P. Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol 2011, 23:1-8.
142. Taboureau O., Baell J.B., Fernández-Recio J., Villoutreix B.O. Established and emerging trends in computational drug discovery in the structural genomics era. Chem Biol 2012, 19:29-41.
143. Panagiotou G., Taboureau O. The impact of network biology in pharmacology and toxicology. SAR QSAR Environ Res 2012, 10.1080/1062936X.2012.657237.
144. Csermely P., Korcsmáros T., Kiss H.J.M., London G., Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery. Pharmacol Ther 2013, 138:333-408.
145. Wu Z., Zhao X.-M., Chen L. A systems biology approach to identify effective cocktail drugs. BMC Syst Biol 2010, 4(Suppl. 2):S7.
146. Geldenhuys W.J., Van der Schyf C.J. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 2013, 8:115-129.
147. Rogawski M.A., Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004, 5:553-564.
148. Mackey C. The anticonvulsants market. Nat Rev Drug Discov 2010, 9:265-266.
149. Margineanu D.G., Klitgaard H. Levetiracetam mechanisms of action. Antiepileptic drugs 2002, 419-427. Lippincott Williams & Wilkins, Philadelphia. 5th ed. R.H. Levy, R.H. Mattson, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
150. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
151. Winden K.D., Karsten S.L., Bragin A., Kudo L.C., Gehman L., Ruidera J., et al. A systems level, functional genomics analysis of chronic epilepsy. PLoS One 2011, 6(6):e20763.
152. Miller G. Is Pharma running out of brainy ideas?. Science 2010, 329:502-504.
153. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions?. Epilepsia 2012, 53(Suppl. 7):26-33.
154. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9:203-214.
155. Cressey D. Traditional drug-discovery model ripe for reform. Nature 2011, 471:17-18.
156. Kitano H., Ghosh S., Matsuoka Y. Social engineering for virtual 'big science' in systems biology. Nat Chem Biol 2011, 7:323-326.
157. Swinney D.C., Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10:507-519.
158. Lee J.A., Uhlik M.T., Moxham C.M., Tomandl D., Sall D.J. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem 2012, 55:4527-4538.
159. Kotz J. Phenotypic screening, take two. SciBX 2012, 5(15). 10.1038/scibx.2012.380.
160. Lu J.-J., Pan W., Hu Y.-J., Wang Y.-T. Multi-target drugs: the trend of drug research and development. PLoS One 2012, 7(6):e40262. 10.1371/journal.pone.0040262.
161. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders. CNS Drugs 2008, 22:27-47.
162. Rogawski M., Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004, 10:685-692.
163. Ban T.A. The role of serendipity in drug discovery. Dialogues Clin Neurosci 2006, 8:335-344.
164. Baumeister A.A., Hawkins M.F., López-Muñoz F. Toward standardized usage of the word serendipity in the historiography of psychopharmacology. J Hist Neurosci 2010, 19:253-270.
165. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006, 15:637-647.
166. Łuszczki J.J. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009, 61:197-216.
167. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010, 9:68-82.